Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 5, 2026 at 4:00...
-
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate,...
-
ICP-B794 demonstrated potent anti-tumor activity in preclinical tumor models and a significantly larger safety window compared to similar drugs.
-
According to BCC Research, the market is expected to grow from $30.2 billion in 2024 to $49.5 billion by 2030 at a CAGR of 8.8%.
-
PharmAla is positioned to supply the US market with MDMA, and is advancing its next-generation patented safer MDMA product for human dosing this year.
-
Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...
-
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and...
-
Oxford, UK – 16th April 2026 - Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a...
-
– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases – – Lead program afimetoran, a potential...
-
Stuart Milstein appointed Chief Platform Officer, bringing decades of experience in oligonucleotide drug development to underpin Aerska’s platform R&DLisa Taylor Ash joins Board of Directors,...